Compare Boeing Co (BA) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boeing Co vs IDEXX Laboratories, Inc. — how do they compare? Boeing Co trades at $231.44 (market cap $184.35B), while IDEXX Laboratories, Inc. trades at $571.01 (market cap $46.22B). The key difference: Boeing Co is far larger — about 4× IDEXX Laboratories, Inc.'s market cap, and Boeing Co pays a 0.03% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| BA | IDXX | |
|---|---|---|
Market Cap | $184.35B | $46.22B |
Volume | 7,591,579 | — |
Sector | Industrials | Health |
52-Week High | $252.15 | $766.68 |
52-Week Low | $179.12 | $526.44 |
Enterprise Value | $210.23B | $47.12B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $232.14, down 0.28% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company's fundamentals reflect a recovery, with 2025 revenue at $89.46B and net income of $2.24B, though valuation ratios like P/E of 83.9 remain elevated. News highlights Boeing's strategic sale of subsidiaries to Archer Aviation, aiming to streamline operations.
Outlook is cautiously optimistic with a consensus price target of $280.83, implying 21% upside. Key opportunities include production ramp-up and backlog growth, while risks involve high debt, volatile cash flows, and competitive pressures. Investors should monitor execution on profitability targets and macroeconomic impacts on aerospace demand.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
